Orthogonal fragmentation mechanism enables new levels of metabolite characterization

Electron activated dissociation on the ZenoTOF 7600 system enables thorough characterization of difficult to classify metabolites

Jason Causon1, Christopher Kochansky2, Kevin Bateman2, Rolf Kern3
1
SCIEX, Canada; 2Merck, USA; 3SCIEX, USA

Abstract

As  drug candidates progress through early to late stage drug discovery, more comprehensive metabolic studies are performed to characterize the site of metabolism, to inform researchers working to improve drug performance. MS/MS data is often required to fully characterize the metabolites, but this is difficult when the resulting metabolites become labile. Here, two orthogonal fragmentation techniques were compared to determine the in vitro metabolism of the drug darunavir. Using the ZenoTOF 7600 system and EAD fragmentation, the confident assignment and differentiation of O- and N-glucuronide conjugates was achieved.

RUO-MKT-02-13174-A_f0

Introduction

Thorough characterization of drug candidate metabolism is a requisite part of early to late stage drug discovery. Early ADME (absorption, distribution, metabolism and excretion) studies are used to determine if a drug candidate is prone to metabolic breakdown or oxidation/conjugation. This is typically done by incubation of a compound in liver microsomes, followed by LC-MS analysis (on a triple quadrupole or high resolution mass spectrometer) of the compound to assess a drop in concentration over time. In many cases, the products of these early assays are not extensively characterized and generally do not represent all of the potential metabolic activity a drug could be exposed to in vivo.

As drug candidates progress through research, more comprehensive metabolic characterization is performed. These studies could involve incubation in hepatocytes, or even analysis of in vivo samples. Samples are generally analyzed on a high resolution mass spectrometer (such as TOF MS) to identify metabolites, but MS1 provides no information about the site of metabolism, which is crucial for assessment of potential toxicity and for providing information to chemists working to improve chemical structures. Fragmentation is required to provide structural information about metabolites. The classic mode of analysis is collisional induced dissociation (CID), which fragments ions by accelerating them in the presence of a neutral gas (N2), yielding consistent and efficient fragmentation. But, in some cases, truly diagnostic fragment ions are not generated by this process (Figure 1).

Glucuronide conjugation can be difficult to thoroughly characterize by MS/MS alone, as the glucuronic acid bond is often very labile both in the ionization source and the collision cell of most mass spectrometers. Electron activated dissociation (EAD) on the ZenoTOF 7600 system is an orthogonal fragmentation technique that is able to generate fragments of glucuronide conjugates that retain the glucuronic acid group, which allows for confident assessment of the site of conjugation.

The drug darunavir, a currently prescribed protease inhibitor, was incubated at 1 µM in rat liver hepatocytes and timepoints were analyzed by LC-MS/MS using the ZenoTOF 7600 system to investigate the in vitro metabolism. Two glucuronide conjugates were identified, one of which could be confidently characterized using both CID and EAD, while the other could only be characterized using the fragments generated by EAD.

Figure 1. Possible glucuronide conjugates of darunavir. Site of conjugation can be difficult to identify using conventional fragmentation methods. 

Key features of the ZenoTOF 7600 system for metabolite identification

  • EAD is a reagent free, tunable technique that is applicable to a broad range of molecule types available on the ZenoTOF 7600 system
  • EAD provides orthogonal, complimentary fragmentation to CID, allowing more thorough, confident metabolic structure elucidation than with CID alone
  • The Zeno trap provides enhanced sensitivity in MS/MS modes, allowing characterization of low level metabolites.